Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

The major differential diagnoses of eosinophilic esophagitis are GERD and peptic strictures. Table 1 describes the differences between GERD and eosinophilic esophagitis. The clinical history ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

Fasenra was approved in 2017 but AZ came up short in its attempts to expand its label to chronic obstructive pulmonary ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

Eupraxia Pharmaceuticals has disclosed additional positive data from its Phase Ib/IIa RESOLVE clinical trial of EP-104GI in treating eosinophilic esophagitis (EoE). The multicentre, open-label ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

A reduction in SDI is a positive outcome for the RESOLVE trial. 2. In the Eosinophilic Esophagitis Histology Scoring System, or EoEHSS, grade indicates the severity of each of the eight ...